Maricel Apuli is CAO at BridgeBio Pharma, Inc. (BBIO). They have made 2 open-market trades across 1 company since 2025, most recently 2026-08-16.
CIK 0002058197
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BBIO | 122,687 | $8.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL · 10b5-1 | 2026-07-30 | 2026-08-03 | $80.06 | $160K | +0.3% | -5.4% | — |
| BBIO | SELL · 10b5-1 | 2026-04-30 | 2026-05-04 | $71.58 | $143K | +0.9% | -5.3% | +15.6% |
| BBIO | SELL · 10b5-1 | 2026-02-26 | 2026-02-27 | $66.00 | $132K | +10.9% | +7.8% | +6.3% |
| BBIO | SELL · 10b5-1 | 2026-02-17 | 2026-02-18 | $74.31 | $38K | -10.7% | -6.6% | -10.0% |
| BBIO | SELL · 10b5-1 | 2025-12-08 | 2025-12-10 | $74.26 | $149K | +4.2% | +4.4% | +0.4% |
| BBIO | SELL | 2025-08-07 | 2025-08-11 | $45.44 | $45K | +3.5% | +9.2% | +29.5% |
| BBIO | SELL | 2025-05-02 | 2025-05-06 | $38.51 | $40K | -8.4% | +3.8% | +29.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.